Pharming Group (NASDAQ:PHAR) Shares Down 4.6% - Time to Sell?

Pharming Group (NASDAQ:PHAR - Get Free Report) shares traded down 4.6% during trading on Tuesday . The stock traded as low as $11.73 and last traded at $11.40. 3,361 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 6,249 shares. The stock had previously closed at $11.95.

Analysts Set New Price Targets

A number of research firms recently weighed in on PHAR. Oppenheimer raised their price target on Pharming Group from $30.00 to $39.00 and gave the company an "outperform" rating in a report on Friday, March 14th. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a report on Thursday, March 20th.

Pharming Group Price Performance

The stock has a 50-day simple moving average of $9.42 and a 200 day simple moving average of $9.08. The stock has a market capitalization of $786.78 million, a P/E ratio of -44.48 and a beta of 0.02. The company has a debt-to-equity ratio of 0.41, a quick ratio of 2.76 and a current ratio of 3.53.

Pharming Group (NASDAQ:PHAR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The business had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. On average, equities analysts forecast that Pharming Group will post -0.2 earnings per share for the current fiscal year.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.